J&J Enters HIV Arena With Prezista; Darunavir Is Tenth Protease Inhibitor

The strength of darunavir's bond with protease may provide Johnson & Johnson/Tibotec's Prezista an advantage against other drugs in the class for treatment-experienced HIV patients